Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration

Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 68(2):116–132. https://doi.org/10.3322/caac.21438

Article  Google Scholar 

Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F (2019) Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control 30(5):489–499. https://doi.org/10.1007/s10552-019-01155-5

Article  Google Scholar 

Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 134(7):783–791. https://doi.org/10.1097/cm9.0000000000001474

Article  Google Scholar 

Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F (2013) Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood 121(23):4729–4739. https://doi.org/10.1182/blood-2012-12-471094

Article  Google Scholar 

Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ (2019) High-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. ACS Cent Sci 5(1):122–144. https://doi.org/10.1021/acscentsci.8b00746

Article  Google Scholar 

Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, Ferguson SM, Mandelkern T, Zheng M, Xu T, Rothberg J, Lichenstein H (2017) Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood 129(13):1768–1778. https://doi.org/10.1182/blood-2016-09-736892

Article  Google Scholar 

Lee C, Peddi S, Anderson C, Su H, Cui H, Epstein AL, MacKay JA (2020) Adaptable antibody nanoworms designed for non-Hodgkin lymphoma. Biomaterials 262:120338. https://doi.org/10.1016/j.biomaterials.2020.120338

Article  Google Scholar 

Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O’Donoghue D, Boulton-Jones M, Mathieson PW (2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381(9868):744–751. https://doi.org/10.1016/s0140-6736(12)61566-9

Article  Google Scholar 

O’Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L (2012) Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 119(7):1717–1725. https://doi.org/10.1182/blood-2011-04-347518

Article  Google Scholar 

Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B (2010) Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115(22):4455–4463. https://doi.org/10.1182/blood-2009-10-251082

Article  Google Scholar 

Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B (2010) Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 28(31):4740–4746. https://doi.org/10.1200/jco.2010.29.2813

Article  Google Scholar 

Yuan T, Yang Y, Chen J, Li W, Li W, Zhang Q, Mi Y, Goswami RS, You JQ, Lin D, Qian MD, Calin S, Liang Y, Miranda RN, Calin GA, Zhou X, Ma L, Zweidler-McKay PA, Liu B, Weng AP, Medeiros LJ, Zhang Y, You MJ (2017) Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. Leukemia 31(11):2355–2364. https://doi.org/10.1038/leu.2017.80

Article  Google Scholar 

Uche UU, Piccirillo AR, Kataoka S, Grebinoski SJ, D’Cruz LM (2018) PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt. J Exp Med 215(12):3165–3179. https://doi.org/10.1084/jem.20172018

Article  Google Scholar 

Bi X, Pohl N, Dong H, Yang W (2013) Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice. J Hematol Oncol 6:8. https://doi.org/10.1186/1756-8722-6-8

Article  Google Scholar 

Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW (2017) Combined inhibition of both p110α and p110β isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER(+) breast cancer. Clin Cancer Res 23(11):2795–2805. https://doi.org/10.1158/1078-0432.ccr-15-2764

Article  Google Scholar 

Narkhede M, Cheson BD (2020) Copanlisib in the treatment of non-Hodgkin lymphoma. Future Oncol 16(26):1947–1955. https://doi.org/10.2217/fon-2020-0195

Article  Google Scholar 

Frustaci AM, Tedeschi A, Deodato M, Zamprogna G, Cairoli R, Montillo M (2020) Duvelisib for the treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother 21(11):1299–1309. https://doi.org/10.1080/14656566.2020.1751123

Article  Google Scholar 

Markham A (2014) Idelalisib: first global approval. Drugs 74(14):1701–1707. https://doi.org/10.1007/s40265-014-0285-6

Article  Google Scholar 

Fan L, Wang C, Zhao L, Wang Z, Zhang X, Liu X, Cao L, Xu W, Li J (2020) SHC014748M, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. Neoplasia (New York, NY) 22(12):714–724. https://doi.org/10.1016/j.neo.2020.10.004

Article  Google Scholar 

Cheung BW, Cartier LL, Russlie HQ, Sawchuk RJ (2005) The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies. Fundam Clin Pharmacol 19(3):347–354. https://doi.org/10.1111/j.1472-8206.2005.00329.x

Article  Google Scholar 

Bouvier d’Yvoire M, Coquerel A, Chretien P, Tremblay D (1993) Pooling plasmas for a rapid answer in pharmacokinetic studies: application to a bioequivalence study of hydrocortisone tablets. Fundam Clin Pharmacol 7(5):253–260. https://doi.org/10.1111/j.1472-8206.1993.tb00239.x

Article  Google Scholar 

Mattsson S, Johansson L, Liniecki J, Nosske D, Stabin M, Leide-Svegborn S, Taylor D (2009) Radiation dose to patients from radiopharmaceuticals, vol 25/3, pp 474–477. https://doi.org/10.1007/978-3-642-03902-7_134

(2007) The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 37(2–4):1–332. https://doi.org/10.1016/j.icrp.2007.10.003

US Food and Drug Administration (2016) Safety testing of drugmetabolites guidance for industry. http://www.fda.gov/down-loads/drugs/guidancecomplianceregulatoryinformation/guid-ances/ucm079266.pdf. Accessed 22 Nov 2016

留言 (0)

沒有登入
gif